Dec 02, 2019 / 01:00PM GMT
Unidentified Participant
Good morning, everybody. Thanks for roughing the weather to join the Protalix BioTherapeutics' discussion on Fabry disease.
Today, our host will be Dr. David Warnock from University of Alabama at Birmingham. And he is joined by Protalix's CFO, Eyal Rubin; and CEO, Dror Bashan.
David G Warnock - University of Alabama at Birmingham - Director of the Division of Nephrology
Good morning. Good morning. It's a pleasure to be here. Always fun to come to New York this time of year. So as mentioned, I'm David Warnock. I am a nephrologist, a kidney doctor. And my academic career was at the University of Alabama in Birmingham for the last 25-some years. I served as the Division Director, Head of the Kidney Program. And in 2008, I recruited my replacement. And so I rode off into the horizon. And for the last 10 years, I've been basically -- I've been on Emeritus status, which means, essentially, I get to do what I want to do. And the focus, really, of my efforts over the last 10 years have largely been on Fabry disease. Alabama is an interesting
Protalix BioTherapeutics, Inc. - Special Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot